Investment Thesis
Viridian Therapeutics is a development-stage pharmaceutical company burning $119.7M quarterly with only $141K in revenue, indicating zero commercial product traction. While the $176.3M cash position and 0.03x debt/equity provide a financial buffer of approximately 14-15 quarters, the company faces existential risk absent successful pipeline monetization. No clear path to profitability is evident from current fundamentals.
Strengths
- $176.3M in cash equivalents provides substantial operational runway at current burn rate
- Fortress balance sheet with low leverage (0.03x debt/equity) and $636M stockholders' equity
- Excellent liquidity ratios (15.15x current/quick) enable flexibility for strategic funding or partnerships
Risks
- Unsustainable quarterly cash burn of -$119.7M against near-zero revenue represents critical solvency risk
- Pre-commercial stage evidenced by $141K revenue indicates failed or delayed pipeline commercialization
- Approximately 1.5-year cash runway until depletion absent revenue growth or additional capital raises; high biotech execution risk
Key Metrics to Watch
- Quarterly revenue growth and product launch timeline
- Operating cash flow trends and cash balance trajectory
- Regulatory milestones, clinical trial data, and pipeline advancement
Financial Metrics
Revenue
141.0K
Net Income
-104.9M
EPS (Diluted)
$-2.98
Free Cash Flow
-119.7M
Total Assets
789.0M
Cash
176.3M
Profitability Ratios
Gross Margin
N/A
Operating Margin
-82,389.4%
Net Margin
-74,397.9%
ROE
-16.5%
ROA
-13.3%
FCF Margin
-84,877.3%
Balance Sheet & Liquidity
Current Ratio
15.15x
Quick Ratio
15.15x
Debt/Equity
0.03x
Debt/Assets
19.4%
Interest Coverage
-387.23x
Long-term Debt
20.9M
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-05-07T10:59:09.934118 |
Data as of: 2026-03-31 |
Powered by Claude AI